Detection of renal impairment as one specific comorbidity factor in multiple myeloma: Multicenter study in 198 consecutive patients

European Journal of Haematology

Volumn 83, Issue 6, 2009, Pages 519-527

  Kleber, Martina ^a   Ihorst, Gabriele ^b   Deschler, Barbara ^a   Jakob, Christian ^c   Liebisch, Peter ^d   Koch, Bernd ^a   Sezer, Orhan ^c   Engelhardt, Monika ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Glomerular filtration rate; Multiple myeloma; Outcome; Prognostic score; Renal impairment

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; COMORBIDITY; CREATININE BLOOD LEVEL; CYTOGENETICS; DETERIORATION; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; COMBINED MODALITY THERAPY; COMORBIDITY; CREATININE; DEXAMETHASONE; DOXORUBICIN; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY DISEASES; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; THALIDOMIDE; TREATMENT OUTCOME; VINCRISTINE;

EID: 70449503311     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01318.x     Document Type: Article

References (34)

1. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990 150 : 1693 1695.
2. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma - a demographic study of 1353 patients. Nordic myeloma study group. Eur J Heamtol 1994 53 : 207 212.
3. Iggo N, Palmer AB, Severn A, Trafford JA, Mufti GJ, Taube D, Parsons V. Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment. Q J Med 1989 270 : 903 910.
4. Innes A, Cuthbert RJ, Russell NH, Morgan AG, Burden RP. Intensive treatment of renal failure in patients with multiple myeloma. Clin Lab Haematol 1994 16 : 149 156.
5. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodyialysis and chemotherapy. Arch Intern Med 1990 150 : 863 869.
6. Knudsen LM, Hjort M, Hippe E. Renal failure in multiple myeloma: reversibilty and impact on the prognosis. Eur J Haemotol 2000 65 : 175 181.
7. Torra R, Bladé J, Cases A, López-Pedret J, Montserrat E, Rozman C, Revert L. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1994 91 : 854 859.
8. Denz U, Haas PS, Wäsch R, Einsele H, Engelhardt M. State of the art therapy in multiple myeloma and future perspectives. Eur J Cancer 2006 42 : 1591 1600.
9. Engelhardt M, Mertelsmann R. 160 years of multiple myeloma: progress and challenges. Eur J Cancer 2006 42 : 1507 1509.
10. Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single. Arch Intern Med 1998 158 : 1889 1893.
11. National Kidney Foundation. Kidney Disease Outcome Quality Initiative (K/DOQI) clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 39 (Suppl. 1 S1 266.
12. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation: National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003 139 : 137 147.
13. Stevens LA, Levey AS. Frequently asked questions about GFR estimates. New York : National Kidney Foundation, 2004.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999 130 : 461 470.
15. Levey AS, Greene T, Kusek J. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000 11 : 155A.
16. Kleber M, Cybulla M, Bauchmüller K, Ihorst G, Koch B, Engelhardt M. Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice. Ann Oncol 2007 18 : 950 958.
17. Satariano WA, Ragland DR. The effect of comorbidity on 3 year survival of women with primary breast cancer. Ann Intern Med 1994 120 : 104 110.
18. Haas PS, Bauchmüller K, Kühnemund A, Finke J, Ihorst G, Engelhardt M. Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period. Ann Hematol 2006 85 : 191 193.
19. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR, Mayo Clinic Myeloma, Amyloid, and Dysproteinemia Group. Current therapy for multiple myloma. Mayo Clin Proc 2002 77 : 813 822.
20. Berger DP, Engelhardt R, Mertelsmann R. Das Rote Buch. In : Wäsch R, Müller C, Finke J, Engelhardt M, eds. Multiple Myeloma, 3rd edn. Germany : Ecomed Landsberg/Lech, 2006 : 562 569.
21. Haas PS, Denz U, Ihorst G, Engelhardt M. Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses. Eur J Haematol 2008 80 : 303 309.
22. Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics 1992 48 : 73 85.
23. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994 86 : 829 835.
24. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplanta and chemotherapy in multiple myeloma: Intergroup Francai du myelome. N Engl J Med 1996 335 : 91 7.
25. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999 93 : 55 65.
26. Lamb EJ, Stowe HJ, Simpson DE, Coakley AJ, Newman DJ, Leahy M. Diagnostic accuracy of cystatin C as a marker of kidney disease in patients with multiple myeloma: calculated glomerular filtration rate formulas are equally useful. Clin Chem 2004 50 : 1848 1851.
27. Terpos E, Katodritou E, Tsiftsakis E, et al. Cystatin C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica 2009 94 : 372 379.
28. Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in myeloma patients: outcome in patients with renal failure. Eur J Haematol 2005 75 : 27 33.
29. San Miguel JF, Lahuerta JJ, García-Sanz R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000 1 : 28 36.
30. Kapoor P, Kumar S, Fonseca R, et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2007 39 : 605 611.
31. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000 5 : 224 237. (Pubitemid 30429942)
32. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005 106 : 2912 2919.
33. Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG, Deeg HJ, Appelbaum FR, Storer B, Storb R. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007 110 : 4606 4613.
34. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008 111 : 446 452.